• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

iPierian

edit

We are using induced pluripotent stem cells for drug discovery and development. Focused on neurodegenerative diseases such as SMA, ALS and Parkinson’s, and other major unmet medical needs.

Milestones

edit

• 
  iPierian added Wesley Chan as Board. (7/5/10)
  Posted 9/8/11 at 6:54am
• 
  iPierian added Karen C. Lam as Director of Finance.
  Posted 9/7/11 at 5:53pm
• 
  iPierian added Nancy Stagliano as CEO.
  Posted 9/7/11 at 5:53pm
• 
  iPierian received $28M in Series B funding. (9/9/10)
  Posted 7/8/10 at 7:02pm via dowjones.com
• 
  iPierian received $3.7M in Grant funding. (10/1/09)
  Posted 10/26/09 at 5:47pm via venturebeat.com
• 
  iPierian received $11.5M in Unattributed funding. (7/8/09)
  Posted 9/28/09 at 2:14am via biocetera.com
• 
  iPierian acquired iZumi Bio. (7/8/09)
  Posted 9/28/09 at 2:11am via biocetera.com

Videos

Screenshots

edit

Above: iPierian Screenshot -- #1
Uploaded: 9/28/09

Sources

1. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming (biocetera.com) [edit]
2. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming (biocetera.com) [edit]
3. iPierian snags $3.7M grant from NIH for cell reprogramming (deals.venturebeat.com) [edit]
4. IPierian Announces Second Close Of Series B Financing At $28M (fis.dowjones.com) [edit]